The clinical effects of Shenlian capsule, trastuzumab combined with SOX regimen in the treatment for HER-2 positive advanced gastric carcinoma

Abstract

Objective To investigate the clinical effects of Shenlian capsule, trastuzumab combined with SOX regimen in the treatment for HER-2 positive advanced gastric carcinoma. Methods A total of 314 patients with HER-2 positive advanced gastric carcinoma in our hospital were randomly divided observation group and control group, 157 cases in each group. The observation group was treated by SOX regimen and trastuzumab, while the control group was given Shenlian capsule on the base of control group. After treatment, the short-term effects in the 2 groups were evaluated. Before and after the treatment, the levels of SDF-1, CXCR4, FSP-l and MRP-l4 in the 2 groups were detected. During the treatment, the rates of neurotoxicity, gastrointestinal reaction, liver function injury, renal function injury, rashes and bone marrow suppression were observed in the 2 groups. After the treatment, 3 years follow-up was performed, the 1 year survival rate, 3 year survival rate, overall survival (OS) and progression-free survival (PFS) were observed. Results After the treatment, the control rate (92.7% vs. 79.9%; Z=3.812, P=0.037) and efficiency rate (78.1% vs. 66.4%; Z=3.712, P=0.039) were significantly higher in treatment group than which in the control group (P<0.05). After the treatment, the levels of SDF-1, CXCR4, FSP-l, MRP-l4 in treatment group were significantly lower than control group (t=4.091, 4.310, 3.972, 3.821, P<0.05). During the treatment, the rates of neurotoxicity, gastrointestinal reaction, liver function injury, renal function injury, rashes, bone marrow suppression were significantly lower in treatment group than control group (χ2=5.182, 4.671, 4.491, 5.091, 5.204, 4.925, P<0.05 or P<0.01). After the treatment, the PFS, OS (t=3.714, 3.612, P<0.05), 3 year survival rate (χ2=3.105, P=0.043) were significantly higher in treatment group than the control group. Conclusions The Shenlian capsule, trastuzumab combined with SOX regimen has a good effect and low toxic effects in the treatment of HER-2 positive advanced gastric carcinoma, and they could prolong the survival time. Key words: Stomach neoplasms; Human epidermal growth factor receptor-2; Trastuzumab; Shenlian capsule; Drug-related side effects and adverse reactions; Comparative effectiveness research